The invention relates generally to osmotic delivery systems for sustained delivery of active agents in fluid environments. More particularly, the invention relates to a flow modulator for delivering an active agent from an osmotic delivery system in a fluid environment.
In the prior-art osmotic delivery system 40 shown in
From the foregoing, there continues to be a desire to provide additional reliability and flow modulator capabilities in osmotic delivery systems.
In one aspect, the invention relates to an osmotic delivery system flow modulator which comprises an outer shell constructed and arranged for positioning in an opening of a reservoir of an osmotic delivery system, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core, the fluid channel being adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.
In another aspect, the invention relates to an osmotic delivery system which comprises a reservoir, a semipermeable plug disposed at a first end of the reservoir to selectively permit flow into the reservoir, a flow modulator disposed at a second end of the reservoir, the flow modulator comprising an internal spiral channel adapted for delivery of an active agent formulation contained in the reservoir to a fluid environment in which the osmotic delivery system operates.
In yet another aspect, the invention relates to an implantable delivery system for an active agent formulation which comprises a reservoir made of an impermeable material, a first chamber in the reservoir containing an osmotic engine, a second chamber in the reservoir containing an active agent formulation, a semipermeable plug disposed at a first end of the reservoir adjacent the first chamber, and a flow modulator as described above disposed at a second end of the reservoir adjacent the second chamber.
Other features and advantages of the invention will be apparent from the following description and the appended claims.
The accompanying drawings, described below, illustrate typical embodiments of the invention and are not to be considered limiting of the scope of the invention, for the invention may admit to other equally effective embodiments. The figures are not necessarily to scale, and certain features and certain view of the figures may be shown exaggerated in scale or in schematic in the interest of clarity and conciseness.
The invention will now be described in detail with reference to a few preferred embodiments, as illustrated in the accompanying drawings. In describing the preferred embodiments, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that the invention may be practiced without some or all of these specific details. In other instances, well-known features and/or process steps have not been described in detail so as not to unnecessarily obscure the invention. In addition, like or identical reference numerals are used to identify common or similar elements.
In
Referring to
The use of abutting/engaging shoulders 216, 218 to prevent expulsion of the inner core 204 from the outer shell 202 into the fluid environment in which the osmotic delivery system operates may be applied to any of the examples shown in
Referring to
The length, the cross-sectional shape, and flow area of the fluid channel 206 may be selected such that the average linear velocity of the active agent formulation through the fluid channel 206 is higher than that of the linear inward influx of materials due to diffusion or osmosis from the fluid environment in which the osmotic delivery system operates. This would have the effect of attenuating or moderating back diffusion, which if not controlled could contaminate the active agent formulation in the osmotic delivery system. The release rate of the active agent formulation can be modified by modifying the geometry of the fluid channel 206, as described below.
The convective flow of an active agent through the fluid channel 206 is determined by the pumping rate of the osmotic delivery system and the concentration of the active agent in the active agent formulation in the reservoir of the osmotic delivery system. The convective flow may be expressed as follows:
Qca=(Q)(Ca) (1)
where Qca is the convective transport of beneficial in mg/day, Q is the overall convective transport of the active agent formulation in cm3/day, and Ca is the concentration of active agent in the active agent formulation within the reservoir of the osmotic delivery system in mg/cm3.
The diffusive flow of active agent out of the fluid channel 206 is a function of active agent concentration and diffusivity and cross-sectional shape and length of the fluid channel 206. The diffusive flow may be expressed as follows:
where Qda is the diffusive transport of the active agent in mg/day, D is the diffusivity through the fluid channel 206 in cm2/day, r is the effective inner radius of the fluid channel 206 in cm, ΔCa is the difference between the concentration of the active agent in the active agent formulation in the reservoir of the osmotic delivery system and the concentration of the active agent in the fluid environment outside of the delivery orifice 205 of the flow modulator 200 in mg/cm3, and L is the (spiral) length of the fluid channel 206 in cm.
In general, the concentration of active agent in the active agent formulation in the osmotic delivery system is much greater than the concentration of the active agent in the fluid environment of use such that the difference, ΔCa can be approximated by the concentration of the active agent within the active agent formulation in the osmotic delivery system, Ca. Thus:
It is generally desirable to keep diffusive flux of the active agent much less than convective flow of the active agent. This is represented as follows:
Equation (4) indicates that the relative diffusive flux decreases with increasing volumetric flow rate and path length, increases with increasing diffusivity and channel radius, and is independent of active agent concentration.
The diffusive flux of water where the fluid channel 206 opens into the osmotic delivery system can be approximated as follows:
Qwd(res)=C0Qe(−QL/D
where Co is the concentration profile of water in mg/cm3, Q is the mass flow rate in mg/day, L is the length of the fluid channel 206 in cm, Dw is the diffusivity of water through the material in the fluid channel 206 in cm2/day, and A is the cross-sectional area of the fluid channel 206 in cm2.
The hydrodynamic pressure drop across the delivery orifice can be calculated as follows:
where Q is the mass flow rate in mg/day, L is the length of the spiral fluid channel in cm, μ is the viscosity of the formulation, and r is the effective inner radius of the fluid channel in cm.
The semipermeable plug 308 is a membrane that controls rate of flow of fluid from the fluid environment in which the osmotic delivery system operates into the reservoir 302. The semipermeable plug 308 allows fluid from the fluid environment to enter the reservoir 302. Compositions in the reservoir 302 are prevented from flowing out of the reservoir 302 through the semipermeable plug 308 because of the semipermeable nature of the semipermeable plug 308. The semipermeable plug 308 may be inserted partially or fully into the open end 306. In the former case, the semipermeable plug 308 may include an enlarged end portion 308a which acts as a stop member engaging an end of the reservoir 302. The outer surface 308b of the semipermeable plug 308 may have protrusions or ribs 308c that engage the inner surface 310 of the reservoir 302, thereby locking the semipermeable plug 308 to the reservoir 302 and allowing a seal to be formed between the reservoir 302 and the semipermeable plug 308. The reservoir 302 may also include undercuts which receive the protrusions 308c on the semipermeable plug 308. Semipermeable materials for the semipermeable plug 308 are those that can conform to the shape of the reservoir 302 upon wetting and that can adhere to the inner surface 310 of the reservoir 302. Typically, these materials are polymeric materials, which can be selected based on the pumping rates and system configuration requirements. Examples of suitable semipermeable materials include, but are not limited to, plasticized cellulosic materials, enhanced polymethyl methacrylates (PMMAs) such as hydroxyethylmethacrylate (HEMA), and elastomeric materials, such as polyurethanes and polyamides, polyether-polyamind copolymers, thermoplastic copolyesters, and the like. Polyurethanes are generally preferred.
Two chambers 312, 314 are defined inside the reservoir 302. The chambers 312, 314 are separated by a partition 316, such as a slidable piston or flexible diaphragm, which is configured to fit within and make sealing contact with the reservoir 302 and to move or deform longitudinally within the reservoir 302. Preferably, the partition 316 is formed of an impermeable resilient material. As an example, the partition 316 may be a slidable piston made of an impermeable resilient material and may include annular ring shape protrusions 316a that form a seal with the inner surface 310 of the reservoir 302. Osmotic engine 318 is disposed in the chamber 314 adjacent the semipermeable plug 308, and an active agent formulation 320 is disposed in the chamber 312 adjacent the flow modulator 200. The partition 316 isolates the active agent formulation 320 from the environmental fluids that are permitted to enter the reservoir 302 through the semipermeable plug 308 such that in use, at steady-state flow, the active agent formulation 320 is expelled through the fluid channel 206 at a rate corresponding to the rate at which fluid from the fluid environment flows into reservoir 302 through the semipermeable plug 308.
The osmotic engine 318 may be in the form of tablets as shown. One or more such tablets may be used. Alternatively, the osmotic engine 318 may have other shape, texture, density, and consistency. For example, the osmotic engine 318 may be in powder or granular form. The osmotic engine 318 may include an osmopolymer. Osmopolymers are hydrophilic polymers that can imbibe aqueous fluids, such as water and biological fluids, and upon imbibing aqueous fluids swell or expand to an equilibrium state and retain a significant portion of the imbibed fluid. Osmopolymers swell or expand to a very high degree, usually exhibiting 2 to 50 fold volume increase. Osmopolymers may or may not be cross-linked. Preferred osmopolymers are hydrophilic polymers that are lightly cross-linked, such cross-links being formed by covalent or ionic bonds or residue crystalline regions after swelling. Osmopolymers can be of plant, animal or synthetic origin. Examples of osmopolymers or hydrophilic polymers suitable for use in the osmotic engine 318 include, but are not limited to, poly (hydroxy-alkyl methacrylate) having a molecular weight of from 30,000 to 5,000,000; polyvinylpyrrolidone (PVP) having a molecular weight of from 10,000 to 360,000; anionic and cationic hydrogels; polyelectrolytes complexes; polyvinyl alcohol having a low acetate residual, cross-linked with glyoxal, formaldehyde, or glutaraldehyde and having a degree of polymerization of from 200 to 30,000, a mixture of methyl cellulose, cross-linked agar and carboxymethyl cellulose; a mixture of hydroxypropyl methylcellulose and sodium carboxymethylcellulose; a mixture of hydroxypropyl ethylcellulose and sodium carboxymethyl cellulose; sodium carboxymethylcellulose; potassium carboxymethylcellulose; a water insoluble, water swellable copolymer formed from a dispersion of finely divided copolymer of maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene cross-linked with from 0.001 to about 0.5 moles of saturated cross-linking agent per mole of maleic anhydride per copolymer; water swellable polymers of N-vinyl lactams; polyoxyethylene-polyoxypropylene gel; polyoxybutylene-polyethylene block copolymer gel; carob gum; polyacrylic gel; polyester gel; polyuria gel; polyether gel; polyamide gel; polycellulosic gel; polygum gel; and initially dry hydrogels that imbibe and absorb water which penetrates the glassy hydrogel and lowers its glass temperature. Other examples of osmopolymers include polymers that form hydrogels, such as CARBOPOL®, acidic carboxypolymer, a polymer of acrylic and cross-linked with a polyallyl sucrose, also known as carboxypolymethylene and carboxyvinyl polymer having a molecular weight of 250,000 to 4,000,000; CYNAMER® polyacrylamides; cross-linked water swellable indene-maleic anhydride polymers; GOOD-RITE® polyacrylic acid having a molecular weight of 80,000 to 200,000; POLYOX® polyethylene oxide polymer having a molecular weight of 100,000 to 5,000,000 and higher; starch graft copolymers; AQUA-KEEPS® acrylate polymer polysaccharides composed of condensed glucose units such as diester cross-linked polygluran; and the like. The osmotic engine 318 may also include an osmagent either in addition to or in lieu of the osmopolymer. Osmagents include inorganic and organic compounds that exhibit an osmotic pressure gradient across a semipermeable wall against an external fluid. Osmagents imbibe fluid into the osmotic system, thereby making available fluid to push against the formulation for delivery through the flow modulator. Osmagents are also known as osmotically effective compounds or solutes. Osmagents useful in the osmotic engine 318 include magnesium sulfate, magnesium chloride, sodium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium acid phosphate, mannitol, urea, inositol, magnesium succinate, tartaric acid, carbohydrates such as raffinose, sucrose, glucose, lactose, sorbitol, and mixtures thereof.
The active agent formulation 320 may include one or more active agents. The active agent may be any physiologically or pharmacologically active substance, particularly those known to be delivered to the body of a human or an animal, such as medicaments, vitamins, nutrients, or the like. Active agents which may be delivered by the osmotic delivery system 300 through the flow modulator 200 include, but are not limited to, drugs that act on infectious diseases, chronic pain, diabetes, the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synoptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, analgesics, local anesthetics, antibiotic agents, anti-inflammatory corticosteroids, ocular drugs and synthetic analogs of these species. Preferred active agents include macromolecules (proteins and peptides) and active agents that are highly potent. The active agent can be present in a wide variety of chemical and physical forms, such as solids, liquids and slurries. In addition to the one or more active agents, the formulation 320 may optionally include pharmaceutically acceptable carriers and/or additional ingredients such as antioxidants, stabilizing agents, buffers, and permeation enhancers.
Materials that are used for the reservoir 302 should be sufficiently rigid to withstand expansion of the osmotic engine 318 without changing its size or shape. Further, the materials should ensure that the reservoir 302 will not leak, crack, break, or distort under stress to which it could be subjected during implantation or under stresses due to the pressures generated during operation. The reservoir 302 may be formed of inert, biocompatible, natural or synthetic materials which are known in the art. The material of the reservoir 302 may or may not bioerodible. A material that is bioerodible will at least in part dissolve, degrade, or otherwise erode in the fluid environment of use. Preferably, the material of the reservoir 302 is non-bioerodible. Generally, preferred materials for the reservoir 302 are those acceptable for human implantation. Preferably, the material of the reservoir 302 is impermeable, particularly when stability of the formulation in the reservoir 302 is sensitive to the fluid environment of use. Examples of materials suitable for the reservoir 302 include non-reactive polymers or biocompatible metals or alloys. Examples of non-reactive polymers for the reservoir 302 include, but are not limited to, acrylonitrile polymers such as acrylonitrile-butadiene-styrene terpolymer; halogenated polymers such as polytetraflouroethylene, polychlorotrifluoroethylene, copolymer tetrafluoroethylene and hexafluoropropylene; polyimide; polysulfone; polycarbonate; polyethylene; polypropylene; polyvinylchloride-acrylic copolymer; polycarbonate-acrylonitrile-butadiene-styrene; and polystyrene. Examples of metallic materials for the reservoir 302 include, but are not limited to, stainless steel, titanium, platinum, tantalum, gold, and their alloys, as well as gold-plated ferrous alloys, platinum-plated ferrous alloys, cobalt-chromium alloys and titanium nitride coated stainless steel. For size-critical applications, high payload capability, long duration applications, and applications where the formulation is sensitive to body chemistry at the implantation site, the reservoir 302 is preferably made of titanium or a titanium alloy having greater than 60%, often greater than 85% titanium.
The diameter of the flow modulator 200 may be selected such that the flow modulator 200 can be press-fitted into the open end 304 of the reservoir 302. It is also possible to include features such as threads on the outer surface 220 of the outer shell 202 and the inner surface 310 of the reservoir 302 for securing the flow modulator 200 to the reservoir 302.
The following examples are illustrative of the invention and are not to be construed as limiting the invention as otherwise described herein.
An osmotic delivery system, as illustrated in
Reservoirs of several osmotic delivery systems, as described above, were filled with 150-μL of the suspension formulation. The semipermeable plug ends of the osmotic delivery systems were placed into glass vials filled with phosphate buffer solution (PBS), and the flow modulator ends of the osmotic delivery systems were placed into glass vials filled with an aqueous release media. The systems were stored or incubated at 5° C. or 30° C., respectively. At specified time points, the release media was removed and exchanged for fresh solution. The sampled release media was analyzed for active agent content using Reversed Phase High Performance Liquid Chromatography (RP-HPLC).
The invention may provide the following advantages. The two-piece flow modulator enables flexibility in design and manufacturability of the flow modulator. The outer shell is not integral with the reservoir and enables the channel in the flow modulator to be inspected prior to insertion of the flow modulator in the reservoir. The two-piece flow modulator minimizes additional mechanical forces on the channel during insertion of the flow modulator in the reservoir. The two-piece flow modulator enables flexibility to optimize the dimensions of the fluid channel by changing the channel on the inner core or flow insert while maintaining a common outer sleeve.
While the invention has been described with respect to a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the invention should be limited only by the attached claims.
The present application claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/898,358, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 20, 2013, and issued as U.S. Pat. No. 8,992,962 on Mar. 31, 2015, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/898,358 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/740,187, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Jan. 12, 2013, and issued as U.S. Pat. No. 8,470,353 on Jun. 25, 2013, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/740,187 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/601,939, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Aug. 31, 2012, and issued as U.S. Pat. No. 8,367,095 on Feb. 5, 2013, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/601,939 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/433,287, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Mar. 29, 2012, and issued as U.S. Pat. No. 8,273,365 on Sep. 25, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/433,287 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/209,328, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Aug. 12, 2011, and issued as U.S. Pat. No. 8,158,150 on Apr. 17, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/209,328 claims a priority benefit as a division (DIV) of U.S. non-provisional patent application Ser. No. 11/755,494, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 30, 2007, and issued as U.S. Pat. No. 8,052,996 on Nov. 8, 2011, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/755,494 claims a priority benefit from U.S. provisional application Ser. No. 60/809,451, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 30, 2006, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/755,494 also claims a priority benefit as a continuation-in-part (CIP) of U.S. non-provisional patent application Ser. No. 11/347,562, entitled “Solvent/Polymer Solutions as Suspension Vehicles,” filed on Feb. 3, 2006, and issued as U.S. Pat. No. 8,114,437 on Feb. 14, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/347,562 claims a priority benefit from U.S. provisional application Ser. No. 60/650,225, entitled “Solvent/Polymer Solutions as Suspension Vehicles,” filed on Feb. 3, 2005, the content of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2110208 | Eggert | Mar 1938 | A |
2168437 | Buercklin | Aug 1939 | A |
3025991 | Gillon | Mar 1962 | A |
3122162 | Sands | Feb 1964 | A |
3625214 | Higuchi | Dec 1971 | A |
3632768 | Bergy et al. | Jan 1972 | A |
3732865 | Higuchi et al. | May 1973 | A |
3797492 | Place | Mar 1974 | A |
3869549 | Geller | Mar 1975 | A |
3987790 | Eckenhoff et al. | Oct 1976 | A |
3995631 | Higuchi et al. | Dec 1976 | A |
3995632 | Nakano et al. | Dec 1976 | A |
4008719 | Theeuwes et al. | Feb 1977 | A |
4034756 | Higuchi et al. | Jul 1977 | A |
4078060 | Benson et al. | Mar 1978 | A |
4111201 | Theeuwes | Sep 1978 | A |
4111202 | Theeuwes | Sep 1978 | A |
4211771 | Witkowski et al. | Jul 1980 | A |
4243030 | Lynch et al. | Jan 1981 | A |
4305927 | Theeuwes et al. | Dec 1981 | A |
4310516 | Chang et al. | Jan 1982 | A |
4340054 | Michaels | Jul 1982 | A |
4350271 | Eckenhoff | Sep 1982 | A |
4373527 | Fischell | Feb 1983 | A |
4376118 | Daher et al. | Mar 1983 | A |
4439196 | Higuchi | Mar 1984 | A |
4455143 | Theeuwes et al. | Jun 1984 | A |
4455145 | Theeuwes | Jun 1984 | A |
4552561 | Eckenhoff et al. | Nov 1985 | A |
4588614 | Lauchenauer | May 1986 | A |
4594108 | Greminger, Jr. et al. | Jun 1986 | A |
4609374 | Ayer | Sep 1986 | A |
4639244 | Rizk et al. | Jan 1987 | A |
4655462 | Balsells | Apr 1987 | A |
4673405 | Guittard et al. | Jun 1987 | A |
4675184 | Hasegawa et al. | Jun 1987 | A |
4695623 | Stabinsky | Sep 1987 | A |
4727138 | Goeddel et al. | Feb 1988 | A |
4734284 | Terada et al. | Mar 1988 | A |
4743449 | Yoshida et al. | May 1988 | A |
4753651 | Eckenhoff | Jun 1988 | A |
4762791 | Goeddel et al. | Aug 1988 | A |
4765989 | Wong et al. | Aug 1988 | A |
4783337 | Wong et al. | Nov 1988 | A |
4820638 | Swetly et al. | Apr 1989 | A |
4826144 | Balsells | May 1989 | A |
4830344 | Balsells | May 1989 | A |
4845196 | Cowling | Jul 1989 | A |
4847079 | Kwan | Jul 1989 | A |
4851228 | Zentner et al. | Jul 1989 | A |
4865845 | Eckenhoff et al. | Sep 1989 | A |
4873080 | Brickl et al. | Oct 1989 | A |
4874388 | Wong et al. | Oct 1989 | A |
4876781 | Balsells | Oct 1989 | A |
4885166 | Meyer et al. | Dec 1989 | A |
4886668 | Haslam et al. | Dec 1989 | A |
4892778 | Theeuwes et al. | Jan 1990 | A |
4893795 | Balsells | Jan 1990 | A |
4897471 | Stabinsky | Jan 1990 | A |
4907788 | Balsells | Mar 1990 | A |
4915366 | Balsells | Apr 1990 | A |
4915949 | Wong et al. | Apr 1990 | A |
4915954 | Ayer et al. | Apr 1990 | A |
4917887 | Hauptmann et al. | Apr 1990 | A |
4917895 | Lee et al. | Apr 1990 | A |
4927687 | Nuwayser | May 1990 | A |
4929554 | Goeddel et al. | May 1990 | A |
4931285 | Edgren et al. | Jun 1990 | A |
4934666 | Balsells | Jun 1990 | A |
4940465 | Theeuwes et al. | Jul 1990 | A |
4952402 | Sparks et al. | Aug 1990 | A |
4961253 | Balsells | Oct 1990 | A |
4964204 | Balsells | Oct 1990 | A |
4969884 | Yum | Nov 1990 | A |
4974821 | Balsells | Dec 1990 | A |
4976966 | Theeuwes et al. | Dec 1990 | A |
5004689 | Fiers et al. | Apr 1991 | A |
5006346 | Theeuwes et al. | Apr 1991 | A |
5019382 | Cummins, Jr. | May 1991 | A |
5023088 | Wong et al. | Jun 1991 | A |
5024842 | Edgren et al. | Jun 1991 | A |
5030216 | Theeuwes et al. | Jul 1991 | A |
5034229 | Magruder et al. | Jul 1991 | A |
5057318 | Magruder et al. | Oct 1991 | A |
5059423 | Magruder et al. | Oct 1991 | A |
5071642 | Lahr et al. | Dec 1991 | A |
5072070 | Balsells | Dec 1991 | A |
5079388 | Balsells | Jan 1992 | A |
5091188 | Haynes | Feb 1992 | A |
5108078 | Balsells | Apr 1992 | A |
5110596 | Magruder et al. | May 1992 | A |
5112614 | Magruder et al. | May 1992 | A |
5113938 | Clayton | May 1992 | A |
5117066 | Balsells | May 1992 | A |
5118666 | Habener | Jun 1992 | A |
5120306 | Gosselin | Jun 1992 | A |
5120712 | Habener | Jun 1992 | A |
5120832 | Goeddel et al. | Jun 1992 | A |
5122128 | Cardinal et al. | Jun 1992 | A |
5126142 | Ayer et al. | Jun 1992 | A |
5134244 | Balsells | Jul 1992 | A |
5137727 | Eckenhoff | Aug 1992 | A |
5151093 | Theeuwes et al. | Sep 1992 | A |
5160122 | Balsells | Nov 1992 | A |
5160743 | Edgren et al. | Nov 1992 | A |
5161806 | Balsells | Nov 1992 | A |
5180591 | Magruder et al. | Jan 1993 | A |
5190765 | Jao et al. | Mar 1993 | A |
5203849 | Balsells | Apr 1993 | A |
5207752 | Sorenson et al. | May 1993 | A |
5209746 | Balaban et al. | May 1993 | A |
5213809 | Wright et al. | May 1993 | A |
5219572 | Sivaramakrishnan | Jun 1993 | A |
5221278 | Linkwitz et al. | Jun 1993 | A |
5223265 | Wong | Jun 1993 | A |
5231176 | Goeddel et al. | Jul 1993 | A |
5234424 | Yum et al. | Aug 1993 | A |
5234692 | Magruder et al. | Aug 1993 | A |
5234693 | Magruder et al. | Aug 1993 | A |
5234695 | Hobbs et al. | Aug 1993 | A |
5252338 | Jao et al. | Oct 1993 | A |
5260069 | Chen | Nov 1993 | A |
5278151 | Korb et al. | Jan 1994 | A |
5279608 | Cherif Cheikh | Jan 1994 | A |
5284655 | Bogdansky et al. | Feb 1994 | A |
5290271 | Jernberg | Mar 1994 | A |
5300302 | Tachon et al. | Apr 1994 | A |
5308348 | Balaban et al. | May 1994 | A |
5312389 | Theeuwes et al. | May 1994 | A |
5312390 | Wong | May 1994 | A |
5318558 | Linkwitz et al. | Jun 1994 | A |
5318780 | Viegas et al. | Jun 1994 | A |
5320616 | Magruder et al. | Jun 1994 | A |
5324280 | Wong et al. | Jun 1994 | A |
5336057 | Fukuda et al. | Aug 1994 | A |
5352662 | Brooks et al. | Oct 1994 | A |
5368588 | Bettinger | Nov 1994 | A |
5368863 | Eckenhoff et al. | Nov 1994 | A |
5371089 | Rattan | Dec 1994 | A |
5374620 | Clark et al. | Dec 1994 | A |
5385738 | Yamahira et al. | Jan 1995 | A |
5411951 | Mitchell | May 1995 | A |
5413572 | Wong et al. | May 1995 | A |
5413672 | Hirotsuji et al. | May 1995 | A |
5424286 | Eng | Jun 1995 | A |
5429602 | Hauser | Jul 1995 | A |
5443459 | Wong et al. | Aug 1995 | A |
5445829 | Paradissis et al. | Aug 1995 | A |
5456679 | Balaban et al. | Oct 1995 | A |
5458888 | Chen | Oct 1995 | A |
5464929 | Bezwada et al. | Nov 1995 | A |
5472708 | Chen | Dec 1995 | A |
5486365 | Takado et al. | Jan 1996 | A |
5498255 | Wong et al. | Mar 1996 | A |
5511355 | Dingler | Apr 1996 | A |
5512293 | Landrau et al. | Apr 1996 | A |
5512549 | Chen et al. | Apr 1996 | A |
5514110 | Teh | May 1996 | A |
5529914 | Hubbell et al. | Jun 1996 | A |
5531736 | Wong et al. | Jul 1996 | A |
5540665 | Mercado et al. | Jul 1996 | A |
5540912 | Roorda et al. | Jul 1996 | A |
5543156 | Roorda et al. | Aug 1996 | A |
5545618 | Buckley et al. | Aug 1996 | A |
5557318 | Gabriel | Sep 1996 | A |
5571525 | Roorda et al. | Nov 1996 | A |
5574008 | Johnson et al. | Nov 1996 | A |
5574137 | Gray et al. | Nov 1996 | A |
5580578 | Oshlack et al. | Dec 1996 | A |
5595751 | Bezwada | Jan 1997 | A |
5595759 | Wright et al. | Jan 1997 | A |
5597579 | Bezwada et al. | Jan 1997 | A |
5602010 | Hauptmann et al. | Feb 1997 | A |
5605688 | Himmler et al. | Feb 1997 | A |
5607687 | Bezwada et al. | Mar 1997 | A |
5609885 | Rivera et al. | Mar 1997 | A |
5614221 | Fjellstrom | Mar 1997 | A |
5614492 | Habener | Mar 1997 | A |
5618552 | Bezwada et al. | Apr 1997 | A |
5620698 | Bezwada et al. | Apr 1997 | A |
5620705 | Dong et al. | Apr 1997 | A |
5633011 | Dong et al. | May 1997 | A |
5635213 | Nystrom et al. | Jun 1997 | A |
5639477 | Maruyama et al. | Jun 1997 | A |
5645850 | Bezwada et al. | Jul 1997 | A |
5648088 | Bezwada et al. | Jul 1997 | A |
5660847 | Magruder et al. | Aug 1997 | A |
5660858 | Parikh et al. | Aug 1997 | A |
5660861 | Jao et al. | Aug 1997 | A |
5668170 | Gyory | Sep 1997 | A |
5676942 | Testa et al. | Oct 1997 | A |
5686097 | Taskovich et al. | Nov 1997 | A |
5690925 | Gray et al. | Nov 1997 | A |
5690952 | Magruder et al. | Nov 1997 | A |
5698213 | Jamiolkowski et al. | Dec 1997 | A |
5700486 | Canal et al. | Dec 1997 | A |
5700583 | Jamiolkowski et al. | Dec 1997 | A |
5703200 | Bezwada et al. | Dec 1997 | A |
5711967 | Juch | Jan 1998 | A |
5713847 | Howard, III et al. | Feb 1998 | A |
5728088 | Magruder et al. | Mar 1998 | A |
5728396 | Peery et al. | Mar 1998 | A |
5733572 | Unger et al. | Mar 1998 | A |
5736159 | Chen et al. | Apr 1998 | A |
5738845 | Imakawa | Apr 1998 | A |
5747058 | Tipton et al. | May 1998 | A |
5756450 | Hahn et al. | May 1998 | A |
5782396 | Mastri et al. | Jul 1998 | A |
5795591 | Lee et al. | Aug 1998 | A |
5795779 | McCormick et al. | Aug 1998 | A |
5807876 | Armistead et al. | Sep 1998 | A |
5814323 | Lyle | Sep 1998 | A |
5817129 | Labrecque et al. | Oct 1998 | A |
5830501 | Dong et al. | Nov 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
5843891 | Sherman | Dec 1998 | A |
5844017 | Jamiolkowski et al. | Dec 1998 | A |
5858746 | Hubbell et al. | Jan 1999 | A |
5859150 | Jamiolkowski et al. | Jan 1999 | A |
5861166 | Eckenhoff | Jan 1999 | A |
5871770 | Magruder et al. | Feb 1999 | A |
5874388 | Hsu | Feb 1999 | A |
5876746 | Jona et al. | Mar 1999 | A |
5882676 | Lee et al. | Mar 1999 | A |
5904935 | Eckenhoff et al. | May 1999 | A |
5906816 | Soos et al. | May 1999 | A |
5906830 | Farinas et al. | May 1999 | A |
5908621 | Glue et al. | Jun 1999 | A |
5928666 | Farinas et al. | Jul 1999 | A |
5932547 | Stevenson et al. | Aug 1999 | A |
5938654 | Wong et al. | Aug 1999 | A |
5939286 | Johnson et al. | Aug 1999 | A |
5942223 | Bazer et al. | Aug 1999 | A |
5948430 | Zerbe et al. | Sep 1999 | A |
5958909 | Habener | Sep 1999 | A |
5962023 | Jamiolkowski et al. | Oct 1999 | A |
5972370 | Eckenhoff et al. | Oct 1999 | A |
5972373 | Yajima et al. | Oct 1999 | A |
5976109 | Heruth | Nov 1999 | A |
5985305 | Peery et al. | Nov 1999 | A |
5997527 | Gumucio et al. | Dec 1999 | A |
5997902 | Maruyama et al. | Dec 1999 | A |
6007805 | Foster et al. | Dec 1999 | A |
6017545 | Modi | Jan 2000 | A |
6022561 | Carlsson et al. | Feb 2000 | A |
6029361 | Newman | Feb 2000 | A |
6060450 | Soos et al. | May 2000 | A |
6069133 | Carlo et al. | May 2000 | A |
6074660 | Jamiolkowski et al. | Jun 2000 | A |
6074673 | Guillen | Jun 2000 | A |
6100346 | Jamiolkowski et al. | Aug 2000 | A |
6113938 | Chen et al. | Sep 2000 | A |
6124261 | Stevenson et al. | Sep 2000 | A |
6124281 | Lewis et al. | Sep 2000 | A |
6127520 | Ueda et al. | Oct 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6130200 | Brodbeck et al. | Oct 2000 | A |
6132420 | Dionne et al. | Oct 2000 | A |
6133249 | Hills | Oct 2000 | A |
6133429 | Davis et al. | Oct 2000 | A |
6147168 | Jamiolkowski et al. | Nov 2000 | A |
6156331 | Peery et al. | Dec 2000 | A |
6172046 | Albrecht | Jan 2001 | B1 |
6174547 | Dong et al. | Jan 2001 | B1 |
6177096 | Zerbe et al. | Jan 2001 | B1 |
6183461 | Matsuura et al. | Feb 2001 | B1 |
6187095 | Labrecque et al. | Feb 2001 | B1 |
6190350 | Davis et al. | Feb 2001 | B1 |
6191102 | DiMarchi et al. | Feb 2001 | B1 |
6204022 | Johnson et al. | Mar 2001 | B1 |
6217906 | Gumucio et al. | Apr 2001 | B1 |
6217908 | Mathiowitz et al. | Apr 2001 | B1 |
6218431 | Schoen et al. | Apr 2001 | B1 |
6224894 | Jamiolkowski et al. | May 2001 | B1 |
6235712 | Stevenson et al. | May 2001 | B1 |
6245357 | Edgren et al. | Jun 2001 | B1 |
6248112 | Gambale et al. | Jun 2001 | B1 |
6251435 | Jamiolkowski et al. | Jun 2001 | B1 |
6258377 | New et al. | Jul 2001 | B1 |
6261584 | Peery et al. | Jul 2001 | B1 |
6268343 | Knudsen et al. | Jul 2001 | B1 |
6270787 | Ayer | Aug 2001 | B1 |
6283949 | Roorda | Sep 2001 | B1 |
6284264 | Zerbe et al. | Sep 2001 | B1 |
6284725 | Coolidge et al. | Sep 2001 | B1 |
6284727 | Kim et al. | Sep 2001 | B1 |
6287295 | Chen et al. | Sep 2001 | B1 |
6329336 | Bridon et al. | Dec 2001 | B1 |
6331311 | Brodbeck et al. | Dec 2001 | B1 |
6372218 | Cummins, Jr. | Apr 2002 | B1 |
6372256 | Jamiolkowski et al. | Apr 2002 | B2 |
6375978 | Kleiner et al. | Apr 2002 | B1 |
6395292 | Peery et al. | May 2002 | B2 |
6403655 | Bezwada et al. | Jun 2002 | B1 |
6419952 | Wong et al. | Jul 2002 | B2 |
6433144 | Morris et al. | Aug 2002 | B1 |
6436091 | Harper et al. | Aug 2002 | B1 |
6447522 | Gambale et al. | Sep 2002 | B2 |
6451974 | Hansen | Sep 2002 | B1 |
6458385 | Jamiolkowski et al. | Oct 2002 | B2 |
6458924 | Knudsen et al. | Oct 2002 | B2 |
6464688 | Harper et al. | Oct 2002 | B1 |
6468961 | Brodbeck et al. | Oct 2002 | B1 |
6471688 | Harper et al. | Oct 2002 | B1 |
6472512 | LaFleur et al. | Oct 2002 | B1 |
6485706 | McCoy et al. | Nov 2002 | B1 |
6506724 | Hiles et al. | Jan 2003 | B1 |
6508808 | Carr et al. | Jan 2003 | B1 |
6514500 | Bridon et al. | Feb 2003 | B1 |
6514517 | Jamiolkowski et al. | Feb 2003 | B2 |
6524305 | Peterson et al. | Feb 2003 | B1 |
6528486 | Larsen et al. | Mar 2003 | B1 |
6541021 | Johnson et al. | Apr 2003 | B1 |
6544252 | Theeuwes et al. | Apr 2003 | B1 |
6551613 | Dong et al. | Apr 2003 | B1 |
6569420 | Chen et al. | May 2003 | B2 |
6572890 | Faour et al. | Jun 2003 | B2 |
6579851 | Goeke et al. | Jun 2003 | B2 |
6592887 | Zerbe et al. | Jul 2003 | B2 |
6593295 | Bridon et al. | Jul 2003 | B2 |
6635268 | Peery et al. | Oct 2003 | B2 |
6670368 | Breault et al. | Dec 2003 | B1 |
6673767 | Brodbeck et al. | Jan 2004 | B1 |
6682522 | Carr et al. | Jan 2004 | B2 |
6703225 | Kojima et al. | Mar 2004 | B1 |
6703359 | Young et al. | Mar 2004 | B1 |
6706689 | Coolidge et al. | Mar 2004 | B2 |
6709671 | Zerbe et al. | Mar 2004 | B2 |
6720407 | Hughes et al. | Apr 2004 | B1 |
6730328 | Maskiewicz et al. | May 2004 | B2 |
6767887 | Hoffmann et al. | Jul 2004 | B1 |
6821949 | Bridon et al. | Nov 2004 | B2 |
6833256 | Pontzer et al. | Dec 2004 | B1 |
6835194 | Johnson et al. | Dec 2004 | B2 |
6840931 | Peterson et al. | Jan 2005 | B2 |
6849708 | Habener | Feb 2005 | B1 |
6849714 | Bridon et al. | Feb 2005 | B1 |
6858576 | Young et al. | Feb 2005 | B1 |
6872700 | Young et al. | Mar 2005 | B1 |
6875748 | Manthorpe et al. | Apr 2005 | B2 |
6887470 | Bridon et al. | May 2005 | B1 |
6887849 | Bridon et al. | May 2005 | B2 |
6899887 | Ayer | May 2005 | B2 |
6902744 | Kolterman et al. | Jun 2005 | B1 |
6903186 | Dong | Jun 2005 | B1 |
6923800 | Chen et al. | Aug 2005 | B2 |
6924264 | Prickett et al. | Aug 2005 | B1 |
6939556 | Lautenbach | Sep 2005 | B2 |
6956026 | Beeley et al. | Oct 2005 | B2 |
6969702 | Bertilsson et al. | Nov 2005 | B2 |
6976981 | Ayer | Dec 2005 | B2 |
6989366 | Beeley et al. | Jan 2006 | B2 |
6992065 | Okumu | Jan 2006 | B2 |
6997922 | Theeuwes et al. | Feb 2006 | B2 |
7014636 | Gilbert | Mar 2006 | B2 |
7022674 | DeFelippis et al. | Apr 2006 | B2 |
7041646 | Pan et al. | May 2006 | B2 |
7074423 | Fereira et al. | Jul 2006 | B2 |
7084243 | Glaesner et al. | Aug 2006 | B2 |
7101567 | Sano et al. | Sep 2006 | B1 |
7101843 | Glaesner et al. | Sep 2006 | B2 |
7112335 | Lautenbach | Sep 2006 | B2 |
7115569 | Beeley et al. | Oct 2006 | B2 |
7138375 | Beeley et al. | Nov 2006 | B2 |
7138486 | Habener et al. | Nov 2006 | B2 |
7141547 | Rosen et al. | Nov 2006 | B2 |
7144863 | DeFelippis et al. | Dec 2006 | B2 |
7153825 | Young et al. | Dec 2006 | B2 |
7157555 | Beeley et al. | Jan 2007 | B1 |
7163688 | Peery et al. | Jan 2007 | B2 |
7199217 | DiMarchi et al. | Apr 2007 | B2 |
7205409 | Pei et al. | Apr 2007 | B2 |
7207982 | Dionne et al. | Apr 2007 | B2 |
7241457 | Chen et al. | Jul 2007 | B2 |
7258869 | Berry et al. | Aug 2007 | B1 |
7297761 | Beeley et al. | Nov 2007 | B2 |
7316680 | Gilbert | Jan 2008 | B2 |
7393827 | Nadler | Jul 2008 | B2 |
7407499 | Trautman | Aug 2008 | B2 |
7442682 | Kitaura et al. | Oct 2008 | B2 |
7456254 | Wright et al. | Nov 2008 | B2 |
7459432 | Cowley et al. | Dec 2008 | B2 |
7521423 | Young et al. | Apr 2009 | B2 |
7563871 | Wright et al. | Jul 2009 | B2 |
7612176 | Wright et al. | Nov 2009 | B2 |
7655254 | Dennis et al. | Feb 2010 | B2 |
7655257 | Peery et al. | Feb 2010 | B2 |
7666835 | Bloom et al. | Feb 2010 | B2 |
7682356 | Alessi | Mar 2010 | B2 |
7727519 | Moran | Jun 2010 | B2 |
7731947 | Eliaz et al. | Jun 2010 | B2 |
7741269 | Young et al. | Jun 2010 | B2 |
7825091 | Bloom et al. | Nov 2010 | B2 |
7829109 | Chen et al. | Nov 2010 | B2 |
7833543 | Gibson et al. | Nov 2010 | B2 |
7879028 | Alessi | Feb 2011 | B2 |
7919109 | Berry et al. | Apr 2011 | B2 |
7959938 | Rohloff et al. | Jun 2011 | B2 |
7964183 | Eliaz et al. | Jun 2011 | B2 |
8048438 | Berry et al. | Nov 2011 | B2 |
8052996 | Lautenbach | Nov 2011 | B2 |
8058233 | Cowley et al. | Nov 2011 | B2 |
8101576 | Bloom | Jan 2012 | B2 |
8114430 | Rohloff et al. | Feb 2012 | B2 |
8114437 | Rohloff | Feb 2012 | B2 |
8158150 | Lautenbach | Apr 2012 | B2 |
8173150 | Berry et al. | May 2012 | B2 |
8206745 | Rohloff | Jun 2012 | B2 |
8211467 | Rohloff | Jul 2012 | B2 |
8217001 | Cowley et al. | Jul 2012 | B2 |
8257691 | Eliaz et al. | Sep 2012 | B2 |
8263545 | Levy et al. | Sep 2012 | B2 |
8263736 | Bloom | Sep 2012 | B2 |
8268341 | Berry | Sep 2012 | B2 |
8273365 | Lautenbach | Sep 2012 | B2 |
8273713 | Pittner et al. | Sep 2012 | B2 |
8278267 | Weyer et al. | Oct 2012 | B2 |
8298561 | Alessi et al. | Oct 2012 | B2 |
8299025 | Alessi et al. | Oct 2012 | B2 |
8343140 | Alessi | Jan 2013 | B2 |
8367095 | Lautenbach | Feb 2013 | B2 |
8372424 | Berry et al. | Feb 2013 | B2 |
8398967 | Eliaz et al. | Mar 2013 | B2 |
8440226 | Rohloff et al. | May 2013 | B2 |
8460694 | Rohloff et al. | Jun 2013 | B2 |
8470353 | Lautenbach | Jun 2013 | B2 |
8801700 | Alessi | Aug 2014 | B2 |
8865202 | Zerbe et al. | Oct 2014 | B2 |
8926595 | Alessi | Jan 2015 | B2 |
8940316 | Alessi et al. | Jan 2015 | B2 |
8992961 | Berry et al. | Mar 2015 | B2 |
8992962 | Lautenbach | Mar 2015 | B2 |
9095553 | Rohloff et al. | Aug 2015 | B2 |
20010012511 | Bezwada et al. | Aug 2001 | A1 |
20010021377 | Jamiolkowski et al. | Sep 2001 | A1 |
20010021822 | Ayer | Sep 2001 | A1 |
20010022974 | Ayer | Sep 2001 | A1 |
20010027311 | Chen et al. | Oct 2001 | A1 |
20010036472 | Wong et al. | Nov 2001 | A1 |
20010037190 | Jung | Nov 2001 | A1 |
20020001631 | Okumu | Jan 2002 | A1 |
20020004481 | Cleland et al. | Jan 2002 | A1 |
20020012818 | Ruppi et al. | Jan 2002 | A1 |
20020034532 | Brodbeck et al. | Mar 2002 | A1 |
20020037309 | Jaworowicz et al. | Mar 2002 | A1 |
20020048600 | Bhatt et al. | Apr 2002 | A1 |
20020136848 | Yoshii et al. | Sep 2002 | A1 |
20020137666 | Beeley et al. | Sep 2002 | A1 |
20020141985 | Pittner et al. | Oct 2002 | A1 |
20020197185 | Jamiolkowski et al. | Dec 2002 | A1 |
20030032947 | Harper et al. | Feb 2003 | A1 |
20030044467 | Brodbeck et al. | Mar 2003 | A1 |
20030045454 | Okumu et al. | Mar 2003 | A1 |
20030059376 | Libbey, III et al. | Mar 2003 | A1 |
20030060425 | Ahlem et al. | Mar 2003 | A1 |
20030104063 | Babcock et al. | Jun 2003 | A1 |
20030108608 | Laridon et al. | Jun 2003 | A1 |
20030108609 | Berry et al. | Jun 2003 | A1 |
20030113380 | Ramstack et al. | Jun 2003 | A1 |
20030118660 | Rickey et al. | Jun 2003 | A1 |
20030138403 | Drustrup | Jul 2003 | A1 |
20030138491 | Tracy et al. | Jul 2003 | A1 |
20030157178 | Chen et al. | Aug 2003 | A1 |
20030170289 | Chen et al. | Sep 2003 | A1 |
20030180364 | Chen et al. | Sep 2003 | A1 |
20030186858 | Arentsen | Oct 2003 | A1 |
20030211974 | Brodbeck et al. | Nov 2003 | A1 |
20030215515 | Truong-Le et al. | Nov 2003 | A1 |
20040001689 | Goldsmith et al. | Jan 2004 | A1 |
20040001889 | Chen et al. | Jan 2004 | A1 |
20040002442 | Pan et al. | Jan 2004 | A1 |
20040022859 | Chen et al. | Feb 2004 | A1 |
20040024068 | Levy et al. | Feb 2004 | A1 |
20040024069 | Chen et al. | Feb 2004 | A1 |
20040029784 | Hathaway | Feb 2004 | A1 |
20040039376 | Peery et al. | Feb 2004 | A1 |
20040097906 | Fereira et al. | May 2004 | A1 |
20040101557 | Gibson et al. | May 2004 | A1 |
20040102762 | Gilbert | May 2004 | A1 |
20040115236 | Chan et al. | Jun 2004 | A1 |
20040142867 | Oi et al. | Jul 2004 | A1 |
20040151753 | Chen et al. | Aug 2004 | A1 |
20040157951 | Wolf | Aug 2004 | A1 |
20040198654 | Glaesner et al. | Oct 2004 | A1 |
20040209801 | Brand et al. | Oct 2004 | A1 |
20040224903 | Berry et al. | Nov 2004 | A1 |
20040225113 | LaFleur et al. | Nov 2004 | A1 |
20040243106 | Ayer | Dec 2004 | A1 |
20040265273 | Li et al. | Dec 2004 | A1 |
20040266683 | Hathaway et al. | Dec 2004 | A1 |
20040266692 | Young et al. | Dec 2004 | A1 |
20050004557 | Russell | Jan 2005 | A1 |
20050008661 | Fereira et al. | Jan 2005 | A1 |
20050009742 | Bertilsson et al. | Jan 2005 | A1 |
20050010196 | Fereira et al. | Jan 2005 | A1 |
20050070883 | Brown et al. | Mar 2005 | A1 |
20050079200 | Rathenow et al. | Apr 2005 | A1 |
20050079202 | Chen et al. | Apr 2005 | A1 |
20050095284 | Trautman | May 2005 | A1 |
20050101943 | Ayer et al. | May 2005 | A1 |
20050106214 | Chen | May 2005 | A1 |
20050112188 | Eliaz et al. | May 2005 | A1 |
20050118206 | Luk et al. | Jun 2005 | A1 |
20050118221 | Blakely et al. | Jun 2005 | A1 |
20050131386 | Freeman et al. | Jun 2005 | A1 |
20050175701 | Pan et al. | Aug 2005 | A1 |
20050201980 | Moran | Sep 2005 | A1 |
20050215475 | Ong et al. | Sep 2005 | A1 |
20050266087 | Junnarkar et al. | Dec 2005 | A1 |
20050271702 | Wright et al. | Dec 2005 | A1 |
20050276856 | Fereira et al. | Dec 2005 | A1 |
20050281879 | Chen et al. | Dec 2005 | A1 |
20060013879 | Brodbeck et al. | Jan 2006 | A9 |
20060014678 | Cowley et al. | Jan 2006 | A1 |
20060030526 | Liu et al. | Feb 2006 | A1 |
20060069029 | Kolterman et al. | Mar 2006 | A1 |
20060084604 | Kitaura et al. | Apr 2006 | A1 |
20060094652 | Levy et al. | May 2006 | A1 |
20060141040 | Chen et al. | Jun 2006 | A1 |
20060142234 | Chen et al. | Jun 2006 | A1 |
20060160736 | Nadler | Jul 2006 | A1 |
20060178304 | Juul-Mortensen et al. | Aug 2006 | A1 |
20060193918 | Rohloff et al. | Aug 2006 | A1 |
20060216242 | Rohloff et al. | Sep 2006 | A1 |
20060233841 | Brodbeck et al. | Oct 2006 | A1 |
20060246138 | Rohloff et al. | Nov 2006 | A1 |
20060251618 | Dennis et al. | Nov 2006 | A1 |
20060263433 | Ayer et al. | Nov 2006 | A1 |
20060264890 | Moberg et al. | Nov 2006 | A1 |
20060280795 | Penhasi et al. | Dec 2006 | A1 |
20060293232 | Levy et al. | Dec 2006 | A1 |
20070027105 | Junnarkar et al. | Feb 2007 | A1 |
20070166352 | Wright et al. | Jul 2007 | A1 |
20070248572 | Moran et al. | Oct 2007 | A1 |
20070281024 | Lautenbach et al. | Dec 2007 | A1 |
20080038316 | Wong et al. | Feb 2008 | A1 |
20080064636 | Bloom et al. | Mar 2008 | A1 |
20080091176 | Alessi et al. | Apr 2008 | A1 |
20080112994 | Junnarkar et al. | May 2008 | A1 |
20080200383 | Jennings et al. | Aug 2008 | A1 |
20080207512 | Roth et al. | Aug 2008 | A1 |
20080226625 | Berry et al. | Sep 2008 | A1 |
20080226689 | Berry et al. | Sep 2008 | A1 |
20080260838 | Hokenson et al. | Oct 2008 | A1 |
20080260840 | Alessi et al. | Oct 2008 | A1 |
20080312157 | Levy et al. | Dec 2008 | A1 |
20090022727 | Houston et al. | Jan 2009 | A1 |
20090042781 | Petersen et al. | Feb 2009 | A1 |
20090074734 | Rottiers | Mar 2009 | A1 |
20090087408 | Berry et al. | Apr 2009 | A1 |
20090156474 | Roth et al. | Jun 2009 | A1 |
20090163447 | Maggio | Jun 2009 | A1 |
20090186817 | Ghosh et al. | Jul 2009 | A1 |
20090202481 | Li et al. | Aug 2009 | A1 |
20090202608 | Alessi et al. | Aug 2009 | A1 |
20090209460 | Young et al. | Aug 2009 | A1 |
20090210019 | Kim et al. | Aug 2009 | A1 |
20090215694 | Kolterman et al. | Aug 2009 | A1 |
20090247463 | Wright et al. | Oct 2009 | A1 |
20090286723 | Levy et al. | Nov 2009 | A1 |
20090312246 | Baron et al. | Dec 2009 | A1 |
20100092566 | Alessi et al. | Apr 2010 | A1 |
20100105627 | Salama et al. | Apr 2010 | A1 |
20100144621 | Kim et al. | Jun 2010 | A1 |
20100185184 | Alessi et al. | Jul 2010 | A1 |
20100297209 | Rohloff et al. | Nov 2010 | A1 |
20110076317 | Alessi et al. | Mar 2011 | A1 |
20110104111 | Rohloff et al. | May 2011 | A1 |
20110152182 | Alsina-Fernandez et al. | Jun 2011 | A1 |
20110160708 | Berry et al. | Jun 2011 | A1 |
20110166554 | Alessi et al. | Jul 2011 | A1 |
20110264077 | Rohloff et al. | Oct 2011 | A1 |
20110306549 | Tatarkiewicz et al. | Dec 2011 | A1 |
20120178687 | Alessi et al. | Jul 2012 | A1 |
20120208755 | Leung | Aug 2012 | A1 |
20130052237 | Eliaz et al. | Feb 2013 | A1 |
20150111818 | Alessi et al. | Apr 2015 | A1 |
20150231256 | Berry et al. | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
0079405 | May 1983 | EP |
0254394 | Jan 1988 | EP |
0295411 | Dec 1988 | EP |
0368339 | May 1990 | EP |
0373867 | Jun 1990 | EP |
0431942 | Jun 1991 | EP |
0379147 | Sep 1994 | EP |
0627231 | Dec 1994 | EP |
0729747 | May 1997 | EP |
0771817 | May 1997 | EP |
0841359 | May 1998 | EP |
0767689 | Jun 1999 | EP |
1046399 | Oct 2000 | EP |
1084703 | Mar 2001 | EP |
1600187 | Jan 2009 | EP |
2020990 | Sep 2010 | EP |
640907 | Jul 1928 | FR |
1049104 | Nov 1966 | GB |
1518683 | Jul 1978 | GB |
9241153 | Sep 1997 | JP |
11-100353 | Apr 1999 | JP |
2006213727 | Aug 2006 | JP |
592113 | Aug 2012 | NZ |
200634060 | Oct 2006 | TW |
WO 9107160 | May 1991 | WO |
WO 9306819 | Apr 1993 | WO |
WO 9306821 | Apr 1993 | WO |
WO 9308832 | May 1993 | WO |
WO 9309763 | May 1993 | WO |
WO 9323083 | Nov 1993 | WO |
WO 9409743 | May 1994 | WO |
WO 9421262 | Sep 1994 | WO |
WO 9501167 | Jan 1995 | WO |
WO 9509006 | Apr 1995 | WO |
WO 9509007 | Apr 1995 | WO |
WO 9534285 | Dec 1995 | WO |
WO 96001134 | Jan 1996 | WO |
WO 9603116 | Feb 1996 | WO |
WO 9639142 | Dec 1996 | WO |
WO 9640049 | Dec 1996 | WO |
WO 9640139 | Dec 1996 | WO |
WO 9640355 | Dec 1996 | WO |
WO 9715289 | May 1997 | WO |
WO 9715296 | May 1997 | WO |
WO 9728181 | Aug 1997 | WO |
WO 9746204 | Dec 1997 | WO |
WO 9747339 | Dec 1997 | WO |
WO 9800152 | Jan 1998 | WO |
WO 9800157 | Jan 1998 | WO |
WO 9800158 | Jan 1998 | WO |
WO 9802169 | Jan 1998 | WO |
WO 9816250 | Apr 1998 | WO |
WO 9817315 | Apr 1998 | WO |
WO 9820930 | May 1998 | WO |
WO 9827960 | Jul 1998 | WO |
WO 9827962 | Jul 1998 | WO |
WO 9827963 | Jul 1998 | WO |
WO 9830231 | Jul 1998 | WO |
WO 9832463 | Jul 1998 | WO |
WO 9842317 | Oct 1998 | WO |
WO 9847487 | Oct 1998 | WO |
WO 9851282 | Nov 1998 | WO |
WO 9903453 | Jan 1999 | WO |
WO 9904767 | Feb 1999 | WO |
WO 9904768 | Feb 1999 | WO |
WO 9916419 | Apr 1999 | WO |
WO 9925728 | May 1999 | WO |
WO 9929306 | Jun 1999 | WO |
WO 9933446 | Jul 1999 | WO |
WO 9933449 | Jul 1999 | WO |
WO 9939700 | Aug 1999 | WO |
WO 9940788 | Aug 1999 | WO |
WO 9944659 | Sep 1999 | WO |
WO 9962501 | Dec 1999 | WO |
WO 9964061 | Dec 1999 | WO |
WO 0013663 | Mar 2000 | WO |
WO 0029206 | May 2000 | WO |
WO 0038652 | Jul 2000 | WO |
WO 0039280 | Jul 2000 | WO |
WO 0040273 | Jul 2000 | WO |
WO 0041548 | Jul 2000 | WO |
WO 0045790 | Aug 2000 | WO |
WO 0054745 | Sep 2000 | WO |
WO 0066138 | Nov 2000 | WO |
WO 0143528 | Jun 2001 | WO |
WO 0151041 | Jul 2001 | WO |
WO 0178683 | Oct 2001 | WO |
WO 0228366 | Apr 2002 | WO |
WO 0236072 | May 2002 | WO |
WO 0243800 | Jun 2002 | WO |
WO 0245752 | Jun 2002 | WO |
WO 0247716 | Jun 2002 | WO |
WO 02067895 | Sep 2002 | WO |
WO 02069983 | Sep 2002 | WO |
WO 02076344 | Oct 2002 | WO |
WO 02085428 | Oct 2002 | WO |
WO 03000230 | Jan 2003 | WO |
WO 03011892 | Feb 2003 | WO |
WO 03024357 | Mar 2003 | WO |
WO 03024503 | Mar 2003 | WO |
WO 03030923 | Apr 2003 | WO |
WO 03041684 | May 2003 | WO |
WO 03072113 | Sep 2003 | WO |
WO 03072133 | Sep 2003 | WO |
WO 2004002565 | Jan 2004 | WO |
WO 2004052336 | Jun 2004 | WO |
WO 2004056338 | Jul 2004 | WO |
WO 2004089335 | Oct 2004 | WO |
WO 2005048930 | Jun 2005 | WO |
WO 2005048952 | Jun 2005 | WO |
WO 2005102293 | Nov 2005 | WO |
WO 2006017772 | Feb 2006 | WO |
WO 2006023526 | Mar 2006 | WO |
WO 2006081279 | Aug 2006 | WO |
WO 2006083761 | Aug 2006 | WO |
WO 2006084139 | Aug 2006 | WO |
WO 2006101815 | Sep 2006 | WO |
WO 2006111169 | Oct 2006 | WO |
WO 2007024700 | Mar 2007 | WO |
WO 2007056681 | May 2007 | WO |
WO 2007075534 | Jul 2007 | WO |
WO 2007084460 | Jul 2007 | WO |
WO 2007133778 | Nov 2007 | WO |
WO 2007140416 | Dec 2007 | WO |
WO 2008021133 | Feb 2008 | WO |
WO 2008061355 | May 2008 | WO |
WO 2008133908 | Nov 2008 | WO |
WO 2008134425 | Nov 2008 | WO |
WO 2009109927 | Sep 2009 | WO |
Entry |
---|
International Search Report and Written Opinion for International Application No. PCT/US2004/010107, mailed Nov. 4, 2004. |
International Preliminary Report on Patentability for International Application No. PCT/US2004/010107, dated Feb. 24, 2005. |
International Search Report and Written Opinion for International Application No. PCT/US2004/010106, mailed Aug. 30, 2004. |
International Preliminary Report on Patentability for International Application No. PCT/US2004/010106, dated Jul. 8, 2005. |
Office Action for U.S. Appl. No. 11/347,562, mailed Feb. 4, 2010, 9 pages. |
Office Action for U.S. Appl. No. 11/347,562, mailed Sep. 7, 2010, 20 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2006/003192, mailed Jul. 28, 2006. |
International Preliminary Report on Patentability for International Application No. PCT/US2006/003192, dated Aug. 7, 2007. |
Office Action for U.S. Appl. No. 12/827,265, mailed Mar. 30, 2011, 10 pages. |
Office Action for U.S. Appl. No. 13/158,137, mailed Dec. 13, 2011, 13 pages. |
Office Action for U.S. Appl. No. 13/526,375, mailed Sep. 14, 2012, 13 pages. |
Office Action for U.S. Appl. No. 12/925,864, mailed Dec. 13, 2011, 11 pages. |
Office Action for U.S. Appl. No. 13/647,228, mailed Jan. 2, 2013, 5 pages. |
Office Action for U.S. Appl. No. 13/647,873, mailed Sep. 11, 2014, 7 pages. |
Office Action for U.S. Appl. No. 13/647,873, mailed Jan. 3, 2013, 5 pages. |
Office Action for U.S. Appl. No. 13/647,873, mailed Jun. 18, 2013, 5 pages. |
Office Action for U.S. Appl. No. 11/755,494, mailed Dec. 27, 2010, 10 pages. |
Office Action for U.S. Appl. No. 11/755,494, mailed Jun. 8, 2011, 15 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2007/069990, mailed Feb. 26, 2008. |
International Preliminary Report on Patentability for International Application No. PCT/US2007/069990, dated Dec. 3, 2008. |
Office Action for U.S. Appl. No. 13/433,287, mailed Jun. 19, 2012, 5 pages. |
Office Action for U.S. Appl. No. 13/601,939, mailed Oct. 25, 2012, 5 pages. |
Office Action for U.S. Appl. No. 13/740,187, mailed Apr. 11, 2013, 6 pages. |
Office Action for U.S. Appl. No. 13/898,358, mailed Jul. 17, 2014, 6 pages. |
Office Action for U.S. Appl. No. 13/209,328, mailed Feb. 16, 2012, 5 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2004/009755, mailed Nov. 22, 2004. |
International Preliminary Report on Patentability for International Application No. PCT/US2004/009755, dated Jul. 8, 2005. |
Office Action for U.S. Appl. No. 12/148,896, mailed Aug. 23, 2012, 6 pages. |
Office Action for U.S. Appl. No. 12/148,896, mailed Oct. 20, 2009, 10 pages. |
Office Action for U.S. Appl. No. 12/148,896, mailed May 14, 2010, 8 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2008/005235, mailed Apr. 11, 2008. |
International Search Report and Written Opinion for International Application No. PCT/US2008/005235, mailed Dec. 19, 2008. |
Office Action for U.S. Appl. No. 12/927,432, mailed Mar. 26, 2014, 8 pages. |
Bell, G. I. et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature, 302:716-718 (1983). |
Clark, J. B. et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol., Med., 173(1): 68-75 (1983). |
Henry, R. R. et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” ITCA 650 phase 2 oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden (Sep. 20-24, 2010). |
Dash, A. K. et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998). |
Deacon, C. F. et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002). |
Efendic, S. et al., et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004). |
Eissele, R. et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994). |
Eng, J. et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990). |
Eng, J. et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992). |
Ghiglione, M., et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia, 27:599-600 (1984). |
Goke, R. et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993). |
Gutniak, M. et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992). |
Heinrich, G. et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984). |
Lopez, L. C. et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983). |
Lund, P. K. et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982). |
Meier, J. J. et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006). |
Mojsov, S., “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992). |
Nauck, M. A. et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998). |
Patzelt, C. et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979). |
Peterson, R. G. et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990). |
Peterson, R. G. et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990). |
Pohl, M. et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998). |
Press Release, Intarcia Therapeutics, Inc., “Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” (Sep. 22, 2010). |
Press Release, “Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatits C Genotype-1 ,” NLV Partners Press Coverage Portofolio News (Apr. 12, 2007). |
Schepp, W. et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994). |
Sparks, J. D. et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998). |
Tseng, C. C. et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993). |
Vrabec, J. T., “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998). |
Young, A. A. et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999). |
Office Action for U.S. Appl. No. 14/605,348, mailed Dec. 4, 2015, 14 pages. |
Office Action for U.S. Appl. No. 14/749,178, mailed Feb. 11, 2016, 9 pages. |
First Office Action for Chinese Patent Application No. 201410262400.X, mailed Dec. 14, 2015, 14 pages. |
“Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism 50(1):S243, ¶ [0586] (Aug. 21, 2007) (XP002538652). |
Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454). |
Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (slides and transcript for presentation at Medscape CME on Dec. 19, 2007). |
“Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209-211 (Dec. 1994). |
Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997). |
Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990). |
Adolf et al., “Antigenic structure of human interferon ω1 (Interferon αll1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987). |
Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990). |
Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991). |
Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005). |
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984). |
Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,”Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999). |
Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,”Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999). |
Aulitzky, “Acute hematologic effects of interferon α, interferon γ, tumor necrosis factor α and Interleukin 2,” Ann. Hemetol. 62(1):25-31 (Feb. 1991). |
Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972). |
Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C” Bioconjugate Chemistry 12(2):195-202 (2001). |
Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996). |
Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems). |
Balkwill, “Interferons,” Lancet 1(8646):1060-1063 (May 1989). |
Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984). |
Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001). |
Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995). |
Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983). |
Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995). |
Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994). |
Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992). |
Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000). |
Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000). |
Boue et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000). |
Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006). |
Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996). |
Cas No. 56-81-5 (Nov. 16, 1984). |
Chang et al., “Biodegradeable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996). |
Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967). |
Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998). |
Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983). |
Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000). |
Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991). |
Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm. 2(11):44-51 (1999). |
Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 570 (Nov. 5-9, 1999). |
Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994). |
Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 569 (Nov. 5-9, 1999). |
Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988). |
Uhlig et al., “The electro-smotic acutation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983). |
Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000). |
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985). |
Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993). |
Fang et al., “The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 572 (Nov. 5-9, 1999). |
Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993). |
Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 977 (May 21-24, 2000). |
Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon α,” Lancet 356(9223):41 (Jul. 2000). |
Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel TiazofurinAnalogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase” J. Medicinal Chem. 38(19):3829-3837 (1995). |
Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001). |
Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (Ddaip),” Int'l J. Pharmaceutics 234(12):121-128 (2002). |
Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract). |
Gan to Kagaku Ryoho, “Phase II study of recombinant leukocyte α interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abtract). |
Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (X0009079028) (non-English with English abstract). |
Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996). |
Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 571 (Nov. 5-9, 1999). |
Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 975 (May 21-24, 2000). |
Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995). |
Grant et al., “Combination therapy with interferon-α plus N-acetyl cystein for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000). |
Hageman, “The Role of Moisture in Protein Stability, ” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988). |
Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000). |
Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000). |
Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998). |
Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998). |
Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994). |
Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993). |
Hodoshima, N. et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997). |
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002). |
Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice,” Cancer Res 59(16):4064-4068 (Aug. 1999). |
Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11(Suppl 5):547-551 (Dec. 1997). |
Jacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer” Am. J. Clin. Oncol. 18(1):27-31 (1995). |
IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993). |
Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002). |
Introduction to Antibodies, http ://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007). |
Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957). |
Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000). |
Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” the Oncologist 12(9):1143-1150 (2007). |
Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0/8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only). |
Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996). |
Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000). |
Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970). |
Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996). |
Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990). |
Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996). |
Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998). |
Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984). |
Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). |
Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000). |
Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 976 (May 21-24, 2000). |
Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986). |
Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994). |
Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996). |
Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978). |
Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 974 (May 21-24, 2000). |
Lee, “Therapy of hepatits C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288). |
Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000). |
Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997). |
Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996). |
Malley et al., “Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001). |
Manning et al, “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989). |
Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965). |
Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982). |
Mchutchison et al., “Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998). |
Mchutchison, et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (X0004716177) (Abstract Only). |
Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000). |
Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C infection,” Liver 13(3):146-150 (Jun. 1993). |
Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972). |
Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953). |
Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001). |
Neumann et al., “IIepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998). |
Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996). |
Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001). |
Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract). |
Ortiz, A. et al., “A differential scanning calorimetry study of the interaction of α tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987). |
Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992). |
Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 973 (May 21-24, 2000). |
Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (X004716169) (Abstract Only). |
Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (X0002511882) (Abstract Only). |
Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211- 218 (Jan. 2000). |
Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998). |
Quesada et al., Interferons in Hematological Malignancies at 487-495 (eds. Baron et al., U. Tex. 1987). |
Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997). |
Rajkuiviar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998). |
Roche Pharmaceuticals, Roferon® -A (Interferon alfa-2a, recombinant), 22 pages (2003). |
Roff et al., “Handbook of Common Polymers,” 72 pages (Cleveland Rubber Co. 1971). |
Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957). |
Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4);554-558 (1989). |
Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999). |
Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):605461 (Dec. 2007). |
Schering Corp., Intron® A for Injection, 6 pages (2001). |
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003). |
Schmalfub, et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997). |
Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992). |
Shiffman et al., “A decline in HCV-RNA level during interferon or ihterferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 567 (Nov. 5-9, 1999). |
Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000). |
Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000). |
Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing MS:MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000). |
Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™ ) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study” Gastroenterology 118(4, Supp. 2), Abstract 236 (2000). |
Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002). |
Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001). |
Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 (Sep. 2005). |
Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000). |
Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997). |
Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000). |
Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer” Cancer Chemother. Pharmacol. 35(6):496-500 (1995). |
Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997). |
Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006). |
Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995). |
Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000). |
Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000). |
Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000). |
Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988). |
Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000). |
Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986). |
Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992). |
Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999). |
Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999). |
Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996). |
Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-160 (Apr. 1989). |
Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998). |
Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000). |
Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998). |
Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996). |
Zhang et al, “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995). |
Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998). |
Ziesche et al., “A preliminary study of long-term treatment with interferon γ-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999). |
Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995). |
Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002). |
Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” 21 pages (oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, Sep. 20-24, 2010). |
Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984). |
Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998). |
Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994). |
Lublin et al., “Defining the clinical course of multiple sclerosis: results of an internatinal survey,” Neurology. 46:907-911 (1996). |
Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009). |
Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005). |
Palmeri et al., “5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327-330 (Oct. 1990). |
Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1990). |
Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multple sclerosis,” Neurology 43:662-667 (1993). |
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009). |
Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011). |
Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010). |
Roberts et al., “The Evolution of the Type I Interferonsl,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998). |
Rohloff et al., “Duros Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008). |
Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope, 1 page (last visited Nov. 14, 2012), available at http://patentscope.wipo.int/search/docservicepdf—pct!id00000008776887. |
Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004). |
Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” pages 1-35 (oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, Sep. 26-29, 2007). |
Written Opinion for International Patent Application No. PCT/US2009/005629 (Apr. 15, 2011) (corresponding to U.S. Appl. No. 12/587,946). |
Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997). |
Number | Date | Country | |
---|---|---|---|
20150231062 A1 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
60809451 | May 2006 | US | |
60650225 | Feb 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11755494 | May 2007 | US |
Child | 13209328 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13898358 | May 2013 | US |
Child | 14632700 | US | |
Parent | 13740187 | Jan 2013 | US |
Child | 13898358 | US | |
Parent | 13601939 | Aug 2012 | US |
Child | 13740187 | US | |
Parent | 13433287 | Mar 2012 | US |
Child | 13601939 | US | |
Parent | 13209328 | Aug 2011 | US |
Child | 13433287 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11347562 | Feb 2006 | US |
Child | 11755494 | US |